WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
US FDA declines to approve Checkpoint Therapeutics` skin cancer therapy
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy...
Cosibelimab is the first PD-L1“blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...
50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination...